Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius Medical Care : Partners with JMS Co. Ltd. to Advance Home Dialysis Treatment in Japan

09/17/2021 | 03:13am EDT

Innovative home dialysis therapies to support Japan’s growing dialysis needs

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has today announced a strategic distribution partnership with JMS Co. Ltd, a provider of medical devices and pharmaceuticals, in Japan. Under the agreement, JMS Co. Ltd. will distribute Fresenius Medical Care’s innovative home dialysis therapies in the Japanese market, providing patients with a wider range of dialysis choices to suit their lifestyle, enhance their wellbeing, and to help address the home healthcare needs of Japan’s aging population.

Japan has what is known as a ‘super-aging society’, with the largest elderly population in the world.1 By 2035, it is projected that 33 per cent of the total population will be aged 65 and over.1 Alongside this accelerated aging, the number of people requiring dialysis in Japan continues to grow each year. At the end of 2018, there were 339,841 people in Japan undergoing dialysis with an average age of almost 69 years.2 Yet the vast majority of these people receive their treatment in dialysis centers, with only 3 per cent undergoing home dialysis – the lowest percentage of home dialysis users in the developed world.2 The combination of increased aging population and dialysis need is placing pressure on the Japanese healthcare system, and it is mandatory for Japanese society to find a solution to these issues for sustainaiblity.3

Expanding the opportunities for home dialysis has the potential to provide clinical benefits to patients, as well as offer greater treatment flexibility that can improve quality of life.4 Home dialysis allows patients to have treatment in the familiar surroundings of their own home, where they can take an active hands-on role in their own care, while avoiding the need to travel to a clinic - and therefore enjoy more flexibility to work, study and/or socialize.4

“Fresenius Medical Care is committed to improving patients’ quality of life through our expertise in chronic kidney disease management”, said Mr Harry de Wit, CEO & President of Fresenius Medical Care Asia Pacific. “Through providing various treatments options to healthcare professionals and patients, we aim to deliver on our vision – to create a future worth living, for patients, worldwide, every day”.

“We are happy to form this strategic partnership with JMS, as we share the same vision about the future of home therapy in Japan. We are confident that our partnership will bring substantial benefits to the Japanese community,” said Mrs Jean DeSombre, Executive Vice President for Mature Asia, Fresenius Medical Care Asia Pacific.

Under the agreement, JMS Co. Ltd will distribute the advanced portfolio of Fresenius Medical Care’s home dialysis systems in Japan, including automatic peritoneal dialysis system. These systems, which have US Federal Drug Authority (FDA) and European CE Mark approvals, are used widely in other developed countries.



  1. Iwata, H., Matsushima, M., Watanabe, T., Sugiyama, Y., Yokobayashi, K., Son, D., Satoi, Y., Yoshida, E., Satake, S., Hinata, Y. and Fujinuma, Y., 2020. The need for home care physicians in Japan – 2020 to 2060. BMC Health Services Research, 20(1), pp.1-11.
  2. Nitta, K., Goto, S., Masakane, I., Hanafusa, N., Taniguchi, M., Hasegawa, T., Nakai, S., Wada, A., Hamano, T., Hoshino, J., Joki, N., Abe, M., Yamamoto, K. and Nakamoto, H., 2020. Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality. Renal Replacement Therapy, 6(1), pp.1-18.
  3. Hanafusa, N. and Fukagawa, M., 2020. Global Dialysis Perspective: Japan. Kidney360, 1(5), pp.416-419.
  4. Walker, R., Howard, K. and Morton, R., 2017. Home hemodialysis: a comprehensive review of patient-centered and economic considerations. ClinicoEconomics and Outcomes Research, Volume 9, pp.149-161.


Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.7 million patients worldwide regularly undergo dialysis treatment. Through its network of more than 4,100 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 346,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at www.freseniusmedicalcare.asia.


This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

© Business Wire 2021
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan maintains a Sell rating
10/21FMC FRESENIUS MEDICAL CARE AG & CO K : Barclays reaffirms its Neutral rating
10/18European ADRs Move Lower in Monday Trading
10/07FMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies maintains a Sell rating
10/07FMC FRESENIUS MEDICAL CARE AG & CO K : NorldLB reiterates its Buy rating
10/07Fresenius Medical Care AG & Co. KGaA acquired Sugerencias Medicas S.A.
10/05FRESENIUS MEDICAL CARE : donates 250,000 euros to UNICEF - battle against COVID-19 pandemi..
10/05FMC FRESENIUS MEDICAL CARE AG & CO K : Barclays reiterates its Neutral rating
09/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the German Securiti..
09/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 41 of the WpHG [the Ge..
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG & CO. KGAA
More recommendations
Financials (USD)
Sales 2021 21 090 M - -
Net income 2021 1 271 M - -
Net Debt 2021 13 395 M - -
P/E ratio 2021 16,2x
Yield 2021 1,96%
Capitalization 20 904 M 20 877 M -
EV / Sales 2021 1,63x
EV / Sales 2022 1,53x
Nbr of Employees 123 538
Free-Float 67,8%
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | FME | DE0005785802 | MarketScreener
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 19
Last Close Price 71,35 $
Average target price 80,88 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Rice Powell Chief Executive Officer
Helen Giza Chief Financial Officer
Dieter Schenk Chairman-Supervisory Board
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors